Clinical Trial Update: A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for AMY-101 targeting gingivitis across Phase 1 and Phase 2 (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gingivitis

Drugs mentioned

• AMY-101 (AMY-101)

Snippet

Sponsor: Amyndas Pharmaceuticals S.A. | Conditions: Gingivitis | Phase 1, Phase 2 | Status: COMPLETED